These new recovery milestones will allow clinicians to pinpoint whether or not a patient is responding to therapy or making the necessary strides toward rehabilitation.

Three-year data from the BIOFLOW-V trial, presented Feb. 23 at the 2020 CRT Congress in National Harbor, Md., reinforce the status of Biotronik’s Orsiro drug-eluting stent as superior to the popular Xience stent.

Researchers on the EXCEL trial have been accused of withholding key mortality data when they first published results suggesting stents were as safe as open-heart surgery in treating patients with left main disease.

Philips is launching a new randomized controlled trial—dubbed DEFINE GPS—to assess patient outcomes after PCI guided by instant wave-Free Ratio measurements and angiograms. 

A review published in Circulation: Cardiovascular Interventions Jan. 24 suggests adjunctive coronary atherectomy is a clinically useful and effective tool for treating severely calcified coronary lesions—but, in reality, it’s rarely used.

When the cardiac and neurovascular catheterization lab at Riverside University Health System Medical Center (RUHS-MC) treated its first patient last February, the opening represented many things to many people.

In just eight years, the world’s first completely robotic “hybrid” heart will be ready for transplant, according to the Daily Mail.

Repeat revascularization isn’t a rare occurrence after PCI or CABG, according to a study of patients with left main coronary artery disease—but it can raise a person’s risk of cardiovascular death by as much as four times.